ArticleJPEN. Journal of parenteral and enteral nutrition2026
Propofol-induced hypertriglyceridemia in critically ill trauma patients requiring nutrition therapy: A descriptive cohort study.
Article in JPEN. Journal of parenteral and enteral nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Propofol-induced hypertriglyceridemia in critically ill trauma patients requiring nutrition therapy: A descriptive cohort study.JPEN. Journal of parenteral and enteral nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to assess the incidence and identify risk factors associated with the development of propofol-induced hypertriglyceridemia in critically ill trauma patients who required nutrition therapy.
methodsAdult patients (aged >17 years) admitted to the trauma intensive care unit who received propofol for >24 h and had a serum triglyceride concentration determination during the infusion were retrospectively evaluated. Hypertriglyceridemia was defined as a serum triglyceride concentration > 400 mg/dL. Potential risk factors for hypertriglyceridemia as well as linear and nonlinear correlative relationships between propofol-associated lipid injectable emulsion dose and serum triglyceride concentration were evaluated.
resultsOne hundred and ninety-five serum triglyceride determinations were obtained from 100 patients. Twenty-five patients (25%) developed hypertriglyceridemia. The greatest risk factor for hypertriglyceridemia was lipid injectable emulsion dose (0.48 [0.36, 0.64] vs 0.28 [0.20, 0.49] g/kg/day; P < 0.01). Those who exhibited hypertriglyceridemia had a higher C-reactive protein (P < 0.02), lower prealbumin (P = 0.001), higher serum creatinine (P < 0.04), and required more days of nutrition therapy (P < 0.03). The hypertriglyceridemia group exhibited a nonlinear concave lipid dose-serum triglyceride concentration response relationship (r = 0.731, P = 0.001) whereas those without hypertriglyceridemia had a flattened and variable linear relationship (r = 0.115, P = 0.34).
conclusionHypertriglyceridemia is common during propofol therapy, reflective of lipid injectable emulsion dose, and is associated with greater inflammation, organ dysfunction, and severe critical illness requiring prolonged nutrition therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.